Table 1 Clinico-pathological characteristics
From: Protein and lipid MALDI profiles classify breast cancers according to the intrinsic subtype
Age, yr | |
Range | 33-73 |
Median | 45 |
Gender | |
Female | 34 (100%) |
AJCC Stage | |
IA | 6 (17.6%) |
IIA | 16 (47.1%) |
IIB | 1 (2.9%) |
IIIA | 9 (26.4%) |
IIIB | 2 (5.9%) |
Location of primary tumor | |
Unilateral | 34 (100%) |
Right | 18 (52.9%) |
Left | 16 (47.1%) |
Bilateral | 0 |
Histologic classification | |
Adenocarcinoma | 30 (88.2%) |
Ductal | 26 (86.7%) |
Lobular | 1 (3.3%) |
Mixed ductal and lobular | 1 (3.3%) |
Mucinous | 2 (6.6%) |
Metaplastic | 4 (11.7%) |
Immunohistochemistry | |
Estrogen receptor (ER) | |
Positive | 24 (70.6%) |
Negative | 10 (29.4%) |
Progesterone receptor (PR) | |
Positive | 26 (76.5%) |
Negative | 8 (23.5%) |
HER2 | |
Positive | 14 (41.2%) |
Negative | 20 (58.8%) |
Ki67 | |
< 15% | 14 (41.2%) |
≥15% | 20 (58.8%) |
Intrinsic subtype | |
Adenocarcinoma | 30 (88.2%) |
Luminal (ER+ and/or PR+) | 18 (60.0%) |
HER2 (HER2+ regardless of ER status) | 7 (23.3%) |
Triple negative (ER-, PR-, and HER2-) | 5 (16.7%) |
Metaplastic | 4 (11.7%) |